Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04056221
Other study ID # CAAE: 5419
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 18, 2019
Est. completion date October 10, 2022

Study information

Verified date March 2023
Source University of Sao Paulo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sjögren's syndrome (SS) is a multisystemic chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, resulting in salivary and lacrimal glands hypofunction, with symptoms of dry eyes and mouth. Xerostomia and xerophthalmia present profound negative impact on patients' quality of life, especially due to difficulties in swallowing, dysarthria, dysgeusia, halitosis and burning tongue, discomfort and visual disturbances that lead to daily activities difficulty such as driving or reading. Although some drugs may improve symptoms and prevent SS complications, they can cause significant adverse effects and even fail to relieve symptoms. Integrative and complementary techniques have become a therapeutic option for SS patients. Scientific evidence has supported the efficacy of acupuncture in relieving symptoms of xerostomia and xerophthalmia. Due to the lack of well-controlled and standardized clinical studies, this study aimed to conduct a randomized and controlled trial to determine the efficacy of acupuncture as a therapeutic option for SS patients' symptoms relief.


Description:

The present study is designed as a 24-month, single centre, double-blind, randomized, controlled, two-arm clinical trial (acupuncture and control). The research will be conducted following the CONSORT recommendations and the STRICTA extension. The study care protocol will consist in acupuncture or control intervention at the selected acupoints (R6, E6,E2, Ig4, VC24, TA23, B2) for 8 weeks, 20 minutes sessions with 12 weeks of follow up. Complementary clinical approaches (sialometry, sialochemistry, Schirmer test, staining with topical lissamine green), and the questionnaires (OHIP-14, Eular Sjögren's Syndrome Patient Reported Index (ESSPRI), Xerostomia Inventory, ocular surface disease index (OSDI) will be performed in weeks 1, 8 and 12. The control group will consist of superficial acupuncture, or placebo, or sham. After all interventions and evaluation methods completed, data will be analyzed for their distribution and homogeneity in order to choose the most appropriate statistical test.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date October 10, 2022
Est. primary completion date December 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults = 18 years old, both genres, who consent to participate of the study - Patients who were diagnosed with SJ according to the criteria of the American College of Rheumatology and the European League against Rheumatism Exclusion Criteria: - Patients who have undergone head and neck radiation therapy; - Patients with a history of neoplasias and salivary gland infections; - Patients with acquired immunodeficiency virus infection, sarcoidosis, viral hepatitis, diabetes mellitus and smokers; - Patients with inability to undergo total saliva collection by established techniques; - Patients who can not attend regular acupuncture sessions; - Patients who had a change in the dosage of medications in use within 6 weeks before the start of the study. - Patients who received acupuncture therapy up to 6 weeks prior to the start of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Acupuncture
Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
Sham acupuncture
The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.

Locations

Country Name City State
Brazil School of Dentistry of Ribeirão Preto, University of São Paulo Ribeirão Preto São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Ana Carolina Fragoso Motta, DDS, PhD

Country where clinical trial is conducted

Brazil, 

References & Publications (6)

Assy Z, Brand HS. A systematic review of the effects of acupuncture on xerostomia and hyposalivation. BMC Complement Altern Med. 2018 Feb 13;18(1):57. doi: 10.1186/s12906-018-2124-x. — View Citation

Deng G, Hou BL, Holodny AI, Cassileth BR. Functional magnetic resonance imaging (fMRI) changes and saliva production associated with acupuncture at LI-2 acupuncture point: a randomized controlled study. BMC Complement Altern Med. 2008 Jul 7;8:37. doi: 10.1186/1472-6882-8-37. — View Citation

Hackett KL, Deane KH, Strassheim V, Deary V, Rapley T, Newton JL, Ng WF. A systematic review of non-pharmacological interventions for primary Sjogren's syndrome. Rheumatology (Oxford). 2015 Nov;54(11):2025-32. doi: 10.1093/rheumatology/kev227. Epub 2015 Jun 30. — View Citation

Hu WL, Wu PC, Pan LY, Yu HJ, Pan CC, Hung YC. Effect of laser acupuncture on dry eye: A study protocol for a 2-center randomized controlled trial. Medicine (Baltimore). 2018 Jun;97(22):e10875. doi: 10.1097/MD.0000000000010875. — View Citation

Jiang Q, Zhang H, Pang R, Chen J, Liu Z, Zhou X. Acupuncture for Primary Sjogren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial. BMC Complement Altern Med. 2017 Jan 19;17(1):61. doi: 10.1186/s12906-017-1559-9. — View Citation

Kim BH, Kim MH, Kang SH, Nam HJ. Optimizing acupuncture treatment for dry eye syndrome: a systematic review. BMC Complement Altern Med. 2018 May 3;18(1):145. doi: 10.1186/s12906-018-2202-0. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from baseline Oral Health Impact Profile (OHIP-14) score at 2 and 3 months. Instrument of data collection which comprises of 14 questions with two questions each under seven domains. The domains include; functional limitation,physical pain, psychological discomfort, physical disability, psychological disability, social disability and handicap. Responses to the questions are based on a Likert scale which ranged from 0- "never" to 4- "always". Before (baseline), immediately after and 1 month after acupuncture treatment.
Primary Changes from baseline Xerostomia Inventory score at at 2 and 3 months. It is an 11-item questionnaire that covers both experiential and behavioral aspects of xerostomia. Scores to the 11 items are summated, providing a single score representing the subjective severity of xerostomia. Before (baseline), immediately after and 1 month after acupuncture treatment.
Primary Changes from baseline The Challacombe scale at at 2 and 3 months. The purpose of this scale is to be able to visually identify and quantify whether your patient has xerostomia (dry mouth) Before (baseline), immediately after and 1 month after acupuncture treatment.
Primary Changes from baseline EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) at 2 and 3 months. There is a 0-10 numerical scale for each of the four domains, dryness, discomfort (including pain), global fatigue and mental fatigue Before (baseline), immediately after and 1 month after acupuncture treatment.
Primary Changes from baseline Ocular Surface Disease Index (OSDI) at 2 and 3 months. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." Before (baseline), immediately after and 1 month after acupuncture treatment.
Secondary Changes from baseline whole unstimulated salivary flow rate at 2 and 3 months. Samples of total saliva (saliva resulting from all salivary glands) will be collected between 8:00 am and 11:00 am, and evaluation of salivary flow will be determined by means of expectoration of saliva in graduated tube of 15 mL for a period of 15 minutes, and the volume obtained will be calculated. Before (baseline), immediately after and 1 month after acupuncture treatment.
Secondary Changes from baseline Schirmer test scores at 2 and 3 months. Objective reflection to the lacrimal gland. Schirmer's test uses paper strips inserted into the eye for several minutes to measure the production of tears Before (baseline), immediately after and 1 month after acupuncture treatment.
Secondary Changes from baseline ocular surface staining at 2 and 3 months. This is a test that uses orange dye (fluorescein) and a blue light to detect foreign bodies in the eye. This test can also detect damage to the cornea. Before (baseline), immediately after and 1 month after acupuncture treatment.
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT04968912 - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Phase 2
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT00809003 - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Completed NCT05005806 - Fish Oil (Omega 3 ) in Sjogren's Syndrome Phase 2/Phase 3
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Terminated NCT04143841 - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Recruiting NCT06104124 - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3
Recruiting NCT05115487 - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting NCT06437652 - An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Recruiting NCT05383677 - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT03938207 - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed NCT04546542 - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05085431 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Early Phase 1
Completed NCT00565526 - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed NCT01369589 - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Phase 1/Phase 2
Completed NCT00001953 - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers N/A